Shattuck Labs, Inc. announced Phase 1 clinical trial data for its lead DR3 blocking antibody, SL-325, showing complete DR3 occupancy at doses of 0.1 mg/kg and higher, with a durable, potentially quarterly dosing-compatible subcutaneous formulation. The company expects to initiate the RECEPTIVE-CD1 Phase 2b trial for Crohn's disease in Q3 2026 and submit an IND for its bispecific candidate SL-846 in the first half of 2027. Additionally, approximately 50.6 million warrants were exercised, which is expected to receive the company approximately $49.3 million in additional gross proceeds. Shattuck Labs, Inc. is a biotechnology company focused on developing DR3 blocking antibodies and bispecific antibodies.
